CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis, today
announced the pricing of its previously announced underwritten public
offering of 3,950,000 shares of its common stock at an offering price of
$1.40 per share. In addition, Myomo has granted the underwriter a 45-day
option to purchase up to an additional 592,500 shares to cover
over-allotments, if any. All of the common shares are being offered by
The Company expects to receive gross proceeds from the offering of
approximately $5.5 million, excluding underwriting discounts and
commissions and other offering-related expenses and excluding any
exercise of the over-allotment option. If the underwriter exercises its
over-allotment option in full, gross proceeds from the offering would be
approximately $6.4 million, excluding underwriting discounts and
commissions and other offering-related expenses.
Myomo intends to use the net proceeds from the offering for working
capital and other general corporate purposes. The offering is expected
to close on or about February 12, 2019, subject to the satisfaction of
customary closing conditions.
National Securities Corporation, a wholly owned subsidiary of National
Holdings Corporation (NASDAQ: NHLD), is acting as sole book-running
manager for the proposed offering.
A shelf registration statement on Form S-3 relating to the shares of
common stock being offered was filed with the Securities and Exchange
Commission (the “SEC”) and is effective. A preliminary prospectus
supplement describing the terms of the offering was filed with the SEC
on February 7, 2019, and is available on the SEC’s website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying base
prospectus relating to this offering may be obtained, when available,
from: National Securities Corporation, Attention: Christopher
Passarelli, 200 Vesey Street, 25th Floor, New York, New York 10281,
telephone: (212) 417-8164 or by email at [email protected];
or on the SEC’s website at http://www.sec.gov.
This announcement shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
offer or sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful.
Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. For more information, please visit www.myomo.com.
All statements in this release that are not based on historical fact are
“forward-looking statements.” While management has based any
forward-looking statements included in this release on its current
expectations, the information on which such expectations were based may
change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially from
those in the forward-looking statements, as a result of various factors
including those risks and uncertainties described in the Risk Factors
and in Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of our recently filed Registration
Statement on Form 10-K, which can be found on the SEC’s website at www.sec.gov.
We urge you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only as
of the date made. Except as otherwise required by the federal securities
laws, we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained herein
(or elsewhere) to reflect any change in our expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based.